Please login to the form below

Not currently logged in
Email:
Password:

Wolters Kluwer drops pharma business

Healthcare information provider and consultancy, Wolters Kluwer, is to divest its pharmaceutical solutions business to focus on supporting other aspects of the healthcare market

Healthcare information provider and consultancy, Wolters Kluwer, is to divest its pharmaceutical solutions business to focus on supporting other aspects of the healthcare market.

Nancy McKinstry, CEO and chairman of the executive board of Wolters Kluwer, said: "The planned divestment of the pharma business will focus our health division on taking full advantage of our leading positions in professional information and clinical decision support solutions, one of the fastest growing areas of health, to deliver enhanced value to our stakeholders."

The company's pharmaceutical business currently includes products such as Source and Adis, with services providing support in development, marketing and distribution. This is made in available through textbooks and journals, electronic drug data, clinical information, and other evidence-based content.

The divestiture is expected to close around the end of the 2011.

27th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Cutting through the noise
AstraZeneca looks to lead an R&D revolution as the company invests in CRISPR and functional genomics drug discovery...
International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...

Infographics